Cell and Gene Therapy Drug Delivery Devices Market Size, Share, Scope Report 2026 to 2035
What is Cell and Gene Therapy Drug Delivery Devices Market Size?
Global Cell and Gene Therapy Drug Delivery Devices Market Size is valued at USD 1.16 Bn in 2025 and is predicted ato reach USD 3.07 Bn by the year 2035 at a 10.6% CAGR during the forecast period for 2026 to 2035.
Cell and Gene Therapy Drug Delivery Devices Market Size, Share & Trends Analysis Report By Products (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Pre-Filled Syringe, and Infusion Bags), Commercialized Drugs, Region, And Segment Forecasts, 2026 to 2035.
Cell and Gene Therapy Drug Delivery Devices Market Key Takeaways:
|
Key Industry Insights & Findings from the Report:
- Increasing prevalence of genetic disorders & chronic diseases driving cell and gene therapy drug delivery devices market.
- An increasing number of FDA approvals for cell & gene therapies & their clinical trials driving cell and gene therapy drug delivery devices market.
- North America dominated the market and accounted for a global revenue share in 2024.
- The key challenge for the cell and gene therapy drug delivery devices market is the high costs associated with the manufacturing of these therapies.
The demand for cell and gene therapy drug delivery devices market is enhancing as there is an increase in the number of patients suffering from cancer, diabetes, and other chronic diseases. Therefore, there is a high need of developing affordable and cost-effective cell and gene therapies. Cell and gene therapy is a clinical procedure of modifying genetic material for the treatment of various diseases. Drug Delivery devices have the capacity to perform multiple functions with the highest degree of smartness. Cell and Gene Therapy Drug Delivery Devices are beneficial in the treatment of respiratory diseases, diabetes, and other cardiovascular disorders.
Spreading awareness regarding the benefits of cell and gene therapy drug delivery devices is expected to propel the product demand. Furthermore, fast adoption of advanced technologies, an invention of new devices according to patient’s requirements, increasing government initiatives for research and development of new therapies and devices, high prevalence of chronic diseases, rising number of clinical trials, and creation of smartphone applications will also help to upscale this market. However, the high cost of manufacturing systems, lack of standard therapy protocols, complex procedures, and shortage of skilled professionals are limiting the growth of this market.
Competitive Landscape
Some of The Key Players in The Cell and Gene Therapy Drug Delivery Devices Market:
- Amgen Inc.
- Bausch & Lomb Incorporated.
- Becton, Dickinson and Company
- Bluebird bio, Inc.
- Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
- Dendreon Pharmaceuticals LLC.
- Helixmith Co., Ltd (ViroMed Co., Ltd)
- Human Stem Cells Institute
- Kite Pharma, Inc.
- Kolon TissueGene, Inc.
- Novartis AG
- Orchard Therapeutics plc.
- Pfizer, Inc.
- Renova Therapeutics
- Spark Therapeutics, Inc.
- uniQure N.V.
- Vericel Corporation
- Other Prominent Players
Market Segmentation
The cell and gene therapy drug delivery devices market can be segmented on the basis of products, Commercialized Drugs, and Regions. On the basis of products, the market can be sub-divided into Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Pre-Filled Syringe, and Infusion Bags. On the basis of Commercialized Drugs, the market is sub-segmented into Luxturna, Kymriah, Provenge, Zolgensma, Yescarta, and Strimvelis. Commercialized Drugs segment is expected to dominate this market, as these drugs are modified and prepared according to patient’s requirements. In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Out of these regions, North America is expected to dominate the market over the forecast period (2019-2031).
Recent Developments:
- In May 2024, Bluebird Bio, Inc. successfully conducted the initial commercial cell collection for LYFGENIA, an FDA-approved gene therapy for sickle cell disease that was authorized in December 2023. LYFGENIA is the gene therapy that has undergone the most extensive research for sickle cell disease, and it has been examined for the longest period of time compared to other treatments in this field.
Cell and Gene Therapy Drug Delivery Devices Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 1.16 Bn |
| Revenue Forecast In 2035 | USD 3.07 Bn |
| Growth Rate CAGR | CAGR of 10.6% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Thousands and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2024 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products, By Commercialized Drugs |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Bausch & Lomb Incorporated., Amgen Inc., Becton, Dickinson and Company, Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Dendreon Pharmaceuticals LLC., Bluebird bio, Inc., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cells Institute, Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., Kolon TissueGene, Inc., Vericel Corporation, uniQure N.V., and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Cell and Gene Therapy Drug Delivery Devices Market Segmentation
Global Cell and Gene Therapy Drug Delivery Devices Market by Products
- Subretinal Injection Cannula
- Extension Tube
- Intravenous Catheter
- Sterile Insulin Syringe
- Pre-Filled Syringe
- Infusion Bags
Global Cell and Gene Therapy Drug Delivery Devices Market by Commercialized Drugs
- Luxturna
- Kymriah
- Provenge
- Zolgensma
- Yescarta
- Strimvelis
Global Cell and Gene Therapy Drug Delivery Devices Market by Region
- Europe
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Europe -
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
North America -
- U.S.
- Canada
Asia Pacific -
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America -
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa -
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Some of the key players of Cell and Gene Therapy Drug Delivery Devices Market are Bausch & Lomb Incorporated., Amgen Inc., Becton, Dickinson and Compa
Cell and Gene Therapy Drug Delivery Devices Market is expected to grow at a 10.6% CAGR during the forecast period for 2026-2035.
Cell and Gene Therapy Drug Delivery Devices Market Size is valued at USD 1.16 Bn in 2025 and is predicted ato reach USD 3.07 Bn by the year 2035.
cell and gene therapy drug delivery devices market can be segmented on the basis of products, Commercialized Drugs, and Regions, Luxturna, Kymriah, Provenge, Zolgensma, Yescarta, and Strimvelis.
North America region is leading the Cell and Gene Therapy Drug Delivery Devices Market.